No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lenalidomide + tafasitamab
Morphosys Press Release - 3 weeks
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
|
CD20 positive
CD20 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
Rixathon (rituximab biosimilar)
|
CD20 positive
CD20 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
Truxima (rituximab biosimilar)
|
CD20 positive
CD20 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
Ruxience (rituximab biosimilar)
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
rituximab + polatuzumab vedotin
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
polatuzumab vedotin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
brentuximab vedotin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
ibrutinib
Sensitive: A2 - Guideline
|
TNFRSF8 positive
TNFRSF8 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
brentuximab vedotin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
MINE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-GemOx
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
GemOx
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
ESHAP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
ICE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
RICE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
carboplatin + rituximab + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
carboplatin + gemcitabine + dexamethasone
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
GDP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
RGDP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
DHAX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
DHAP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-DHAP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
EPOCH-R
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
CEOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
CEPP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-ESHAP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-GCVP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CEOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CEPP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CDOP
Sensitive: A2 - Guideline
|
MYC rearrangement + BCL6 rearrangement
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel
Sensitive: A2 - Guideline
|
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel
Sensitive: A2 - Guideline
|
MYC rearrangement + BCL2 rearrangement
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mediastinal B Cell Lymphoma
Mediastinal B Cell Lymphoma
|
lisocabtagene maraleucel
Sensitive: A2 - Guideline
|
MYC overexpression + BCL2 overexpression
MYC overexpression + BCL2 overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
ibrutinib
Sensitive: B - Late Trials
|
MYC rearrangement + BCL2 rearrangement
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lenalidomide
Sensitive: B - Late Trials
|
MYC rearrangement
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lenalidomide
Sensitive: B - Late Trials
|
LDH elevation
LDH elevation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lenalidomide
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
ALLO-501A
Sensitive: B - Late Trials
|
EZH2 mutation
EZH2 mutation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
tazemetostat
Sensitive: C1 - Off-label
|
CD20 positive
CD20 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
rituximab
Sensitive: C1 - Off-label
|
BCL2 expression
BCL2 expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
venetoclax + obinutuzumab
Sensitive: C2 – Inclusion Criteria
|
CD79B mutation
CD79B mutation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
ibrutinib
Sensitive: C2 – Inclusion Criteria
|
MYC expression
MYC expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
RG6146
Sensitive: C2 – Inclusion Criteria
|
BIRC5 expression
BIRC5 expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
pembrolizumab + maveropepimut-S
Sensitive: C2 – Inclusion Criteria
|
MYC rearrangement
MYC rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel
Sensitive: C2 – Inclusion Criteria
|
BCL6 rearrangement
BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel
Sensitive: C2 – Inclusion Criteria
|
CD20 positive
CD20 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
GEN3013
Sensitive: C2 – Inclusion Criteria
|
BCL2 rearrangement
BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
rituximab
Sensitive: C2 – Inclusion Criteria
|
TNFRSF8 expression
TNFRSF8 expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
rituximab + brentuximab vedotin
Sensitive: C2 – Inclusion Criteria
|
MYC overexpression
MYC overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T
Resistant: C3 – Early Trials
|
MYC negative
MYC negative
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T
Sensitive: C3 – Early Trials
|
MYC positive
MYC positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T
Sensitive: C3 – Early Trials
|
MAD2L2 overexpression
MAD2L2 overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
rituximab
Resistant: C3 – Early Trials
|
CRTAM overexpression
CRTAM overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
BTLA overexpression
BTLA overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
LEF1 overexpression
LEF1 overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
KLHL14 mutation
KLHL14 mutation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
LRP1B mutation
LRP1B mutation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
PD-L1 overexpression
PD-L1 overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
BCL2 positive
BCL2 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
methotrexate
Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
cytarabine + methotrexate
Resistant: C3 – Early Trials
|
BCL2 expression + MYC expression
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
methotrexate
Resistant: C3 – Early Trials
|
BCL2 expression + MYC expression
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
cytarabine + methotrexate
Resistant: C3 – Early Trials
|
BCL2 rearrangement
BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
EPOCH-R
Sensitive: C3 – Early Trials
|
LDH elevation
LDH elevation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
ViPOR
Sensitive: C3 – Early Trials
|
BCL6 translocation
BCL6 translocation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
BCL2 expression + MYC expression
BCL2 expression + MYC expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
MYC translocation + BCL2 translocation
MYC translocation + BCL2 translocation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
MYC translocation + BCL6 translocation
MYC translocation + BCL6 translocation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
MYC positive + BCL2 positive
MYC positive + BCL2 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
|
MYC positive + BCL2 positive + BCL6 positive
MYC positive + BCL2 positive + BCL6 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
|
BCL2 amplification
BCL2 amplification
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
BCL2 positive
BCL2 positive
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
venetoclax
Sensitive: C3 – Early Trials
|
CD20 overexpression
CD20 overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
MYC overexpression + BCL2 overexpression
MYC overexpression + BCL2 overexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
|
CD34 underexpression
CD34 underexpression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
MYD88 L265P + CD79B mutation
MYD88 L265P + CD79B mutation
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
miR-6860-5p expression
miR-6860-5p expression
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
MYC rearrangement + BCL2 rearrangement
|
Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
|
rituximab
Resistant: C3 – Early Trials
|
